The leukapheresis device market size has grown strongly in recent years. It will grow from $0.7 billion in 2025 to $0.76 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to rising prevalence of leukemia and autoimmune disorders, adoption of stem cell therapies, advancements in blood cell separation technology, increasing clinical research activities, growth of hospital-based apheresis services.
The leukapheresis device market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to demand for portable leukapheresis systems, integration of ai and automation in devices, expansion of biopharmaceutical research, regulatory approvals for advanced apheresis devices, rising investments in precision medicine. Major trends in the forecast period include personalized leukapheresis treatments, minimally invasive apheresis techniques, portable and point-of-care leukapheresis devices, integration of real-time monitoring systems, enhanced automation and workflow efficiency.
The increasing incidence of blood-related disorders is expected to drive the growth of the leukapheresis device market in the coming years. Blood-related disorders are medical conditions that affect the structure or function of blood cells, leading to issues with oxygen transport, immune system performance, or blood clotting. The growing prevalence of these disorders is largely linked to an aging population, as older adults are more prone to conditions such as anemia, leukemia, and other hematological diseases. Leukapheresis devices support the treatment of these disorders by selectively removing excess or abnormal white blood cells from the blood, thereby helping to relieve symptoms and minimize complications in illnesses like leukemia and autoimmune disorders. For example, in March 2024, the Leukaemia Foundation, an Australia-based non-profit organization, reported that approximately 19,500 Australians were diagnosed with blood cancers, including leukemia, lymphoma, and myeloma, with nearly 43% facing substantial out-of-pocket treatment expenses and 42% needing more than three months off work. This highlights both the rising occurrence and the financial impact on patients and their families compared to previous years. Consequently, the growing prevalence of blood-related disorders is fueling the expansion of the leukapheresis device market.
Key players in the leukapheresis device market are increasingly investing in regional production capabilities to improve access to therapeutic devices and align with national healthcare strategies. Establishing local manufacturing facilities helps to streamline supply chains, reduce reliance on imports, and enhance the affordability and availability of advanced blood and cell collection systems. For instance, in November 2024, Terumo Blood and Cell Technologies, a US-based medical technology firm, collaborated with its China-based subsidiary, Terumo Medical Products (Hangzhou) Co., Ltd., to initiate localized production in Hangzhou. This initiative focuses on producing vital leukapheresis products, such as the Trima Accel Automated Blood Collection System and the Spectra Optia Apheresis System, which are widely used in China for procedures including therapeutic apheresis, stem cell collection, and blood component separation.
In November 2025, Terumo Blood and Cell Technologies (Terumo BCT), a US-based medical technology company, joined forces with Santersus AG to advance an innovative therapeutic apheresis technology aimed at enhancing clinical outcomes for patients with sepsis. Through this collaboration, Terumo BCT and Santersus plan to integrate Santersus’ NucleoCapture blood purification device with Terumo BCT’s Spectra Optia™ Apheresis System to selectively remove neutrophil extracellular traps (NETs) from the blood, potentially lowering sepsis-related mortality and improving patient care. Santersus AG, based in Switzerland, specializes in therapeutic apheresis and develops medical devices for blood purification in critically ill patients.
Major companies operating in the leukapheresis device market are Fresenius SE and Co. KGaA, Asahi Kasei Medical Co. Ltd, Baxter International Inc., Grifols S.A., TERUMO BCT INC., Kaneka Corporation, Nikkiso Co. Ltd, Haemonetics Corporation, Miltenyi Biotec GmbH, Macopharma, B. Braun Melsungen AG, Kawasumi Laboratories Inc., Beijing Zksk Technology Co. Ltd, Puriblood Medical Co. Ltd, Fresenius Kabi AG, JMS Co. Ltd, HemaCare Corporation, Medica Group PLC, LivaNova PLC, Cytiva, BioSafe Group SA, Terumo Corporation.
North America was the largest region in the leukapheresis device market in 2025. The regions covered in the leukapheresis device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukapheresis device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the leukapheresis device market by affecting the cost of imported medical equipment, consumables, and advanced apheresis components. This has increased production and operational costs, particularly impacting segments such as leukapheresis machines, disposable kits, and research-focused apheresis platforms in regions like North America and Europe. While the tariffs pose challenges in terms of supply chain delays, they also encourage local manufacturing and sourcing strategies, enabling some domestic players to capture market share and invest in innovation for cost-efficient leukapheresis solutions.
The leukapheresis device market research report is one of a series of new reports that provides leukapheresis device market statistics, including leukapheresis device industry global market size, regional shares, competitors with a leukapheresis device market share, detailed leukapheresis device market segments, market trends and opportunities, and any further data you may need to thrive in the leukapheresis device industry. This leukapheresis device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A leukapheresis device is a specialized medical tool designed to selectively isolate and collect white blood cells (leukocytes) from the blood of a patient or donor through centrifugation or filtration methods. It serves an essential function in therapies such as leukemia treatment, stem cell transplantation, and autoimmune disorder management, and is also utilized in clinical research and diagnostic procedures.
The primary categories of leukapheresis devices include therapeutic leukapheresis, cytapheresis, stem cell collection, research applications, leukapheresis columns and cell separators, leukapheresis disposables, and apheresis devices. Therapeutic leukapheresis is a medical technique employed to extract surplus or abnormal white blood cells from the bloodstream, aiming to alleviate symptoms or avoid related complications. These systems comprise various elements, including leukapheresis machines, blood collection sets, medical consumables, and filtration components. The diverse group of end users includes hospitals, academic and research organizations, pharmaceutical and biotechnology firms, blood centers, and providers of blood components.
The leukapheresis device market consists of sales of leukapheresis software and monitoring systems, blood flow controllers and pumps, and centrifuge rotors and tubing sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The leukapheresis device market size is expected to see strong growth in the next few years. It will grow to $1.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to demand for portable leukapheresis systems, integration of ai and automation in devices, expansion of biopharmaceutical research, regulatory approvals for advanced apheresis devices, rising investments in precision medicine. Major trends in the forecast period include personalized leukapheresis treatments, minimally invasive apheresis techniques, portable and point-of-care leukapheresis devices, integration of real-time monitoring systems, enhanced automation and workflow efficiency.
The increasing incidence of blood-related disorders is expected to drive the growth of the leukapheresis device market in the coming years. Blood-related disorders are medical conditions that affect the structure or function of blood cells, leading to issues with oxygen transport, immune system performance, or blood clotting. The growing prevalence of these disorders is largely linked to an aging population, as older adults are more prone to conditions such as anemia, leukemia, and other hematological diseases. Leukapheresis devices support the treatment of these disorders by selectively removing excess or abnormal white blood cells from the blood, thereby helping to relieve symptoms and minimize complications in illnesses like leukemia and autoimmune disorders. For example, in March 2024, the Leukaemia Foundation, an Australia-based non-profit organization, reported that approximately 19,500 Australians were diagnosed with blood cancers, including leukemia, lymphoma, and myeloma, with nearly 43% facing substantial out-of-pocket treatment expenses and 42% needing more than three months off work. This highlights both the rising occurrence and the financial impact on patients and their families compared to previous years. Consequently, the growing prevalence of blood-related disorders is fueling the expansion of the leukapheresis device market.
Key players in the leukapheresis device market are increasingly investing in regional production capabilities to improve access to therapeutic devices and align with national healthcare strategies. Establishing local manufacturing facilities helps to streamline supply chains, reduce reliance on imports, and enhance the affordability and availability of advanced blood and cell collection systems. For instance, in November 2024, Terumo Blood and Cell Technologies, a US-based medical technology firm, collaborated with its China-based subsidiary, Terumo Medical Products (Hangzhou) Co., Ltd., to initiate localized production in Hangzhou. This initiative focuses on producing vital leukapheresis products, such as the Trima Accel Automated Blood Collection System and the Spectra Optia Apheresis System, which are widely used in China for procedures including therapeutic apheresis, stem cell collection, and blood component separation.
In November 2025, Terumo Blood and Cell Technologies (Terumo BCT), a US-based medical technology company, joined forces with Santersus AG to advance an innovative therapeutic apheresis technology aimed at enhancing clinical outcomes for patients with sepsis. Through this collaboration, Terumo BCT and Santersus plan to integrate Santersus’ NucleoCapture blood purification device with Terumo BCT’s Spectra Optia™ Apheresis System to selectively remove neutrophil extracellular traps (NETs) from the blood, potentially lowering sepsis-related mortality and improving patient care. Santersus AG, based in Switzerland, specializes in therapeutic apheresis and develops medical devices for blood purification in critically ill patients.
Major companies operating in the leukapheresis device market are Fresenius SE and Co. KGaA, Asahi Kasei Medical Co. Ltd, Baxter International Inc., Grifols S.A., TERUMO BCT INC., Kaneka Corporation, Nikkiso Co. Ltd, Haemonetics Corporation, Miltenyi Biotec GmbH, Macopharma, B. Braun Melsungen AG, Kawasumi Laboratories Inc., Beijing Zksk Technology Co. Ltd, Puriblood Medical Co. Ltd, Fresenius Kabi AG, JMS Co. Ltd, HemaCare Corporation, Medica Group PLC, LivaNova PLC, Cytiva, BioSafe Group SA, Terumo Corporation.
North America was the largest region in the leukapheresis device market in 2025. The regions covered in the leukapheresis device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leukapheresis device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the leukapheresis device market by affecting the cost of imported medical equipment, consumables, and advanced apheresis components. This has increased production and operational costs, particularly impacting segments such as leukapheresis machines, disposable kits, and research-focused apheresis platforms in regions like North America and Europe. While the tariffs pose challenges in terms of supply chain delays, they also encourage local manufacturing and sourcing strategies, enabling some domestic players to capture market share and invest in innovation for cost-efficient leukapheresis solutions.
The leukapheresis device market research report is one of a series of new reports that provides leukapheresis device market statistics, including leukapheresis device industry global market size, regional shares, competitors with a leukapheresis device market share, detailed leukapheresis device market segments, market trends and opportunities, and any further data you may need to thrive in the leukapheresis device industry. This leukapheresis device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A leukapheresis device is a specialized medical tool designed to selectively isolate and collect white blood cells (leukocytes) from the blood of a patient or donor through centrifugation or filtration methods. It serves an essential function in therapies such as leukemia treatment, stem cell transplantation, and autoimmune disorder management, and is also utilized in clinical research and diagnostic procedures.
The primary categories of leukapheresis devices include therapeutic leukapheresis, cytapheresis, stem cell collection, research applications, leukapheresis columns and cell separators, leukapheresis disposables, and apheresis devices. Therapeutic leukapheresis is a medical technique employed to extract surplus or abnormal white blood cells from the bloodstream, aiming to alleviate symptoms or avoid related complications. These systems comprise various elements, including leukapheresis machines, blood collection sets, medical consumables, and filtration components. The diverse group of end users includes hospitals, academic and research organizations, pharmaceutical and biotechnology firms, blood centers, and providers of blood components.
The leukapheresis device market consists of sales of leukapheresis software and monitoring systems, blood flow controllers and pumps, and centrifuge rotors and tubing sets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Leukapheresis Device Market Characteristics
3. Leukapheresis Device Market Supply Chain Analysis
4. Global Leukapheresis Device Market Trends and Strategies
5. Leukapheresis Device Market Analysis of End Use Industries
7. Global Leukapheresis Device Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Leukapheresis Device Total Addressable Market (TAM) Analysis for the Market
9. Leukapheresis Device Market Segmentation
10. Leukapheresis Device Market Regional and Country Analysis
11. Asia-Pacific Leukapheresis Device Market
12. China Leukapheresis Device Market
13. India Leukapheresis Device Market
14. Japan Leukapheresis Device Market
15. Australia Leukapheresis Device Market
16. Indonesia Leukapheresis Device Market
17. South Korea Leukapheresis Device Market
18. Taiwan Leukapheresis Device Market
19. South East Asia Leukapheresis Device Market
20. Western Europe Leukapheresis Device Market
21. UK Leukapheresis Device Market
22. Germany Leukapheresis Device Market
23. France Leukapheresis Device Market
24. Italy Leukapheresis Device Market
25. Spain Leukapheresis Device Market
26. Eastern Europe Leukapheresis Device Market
27. Russia Leukapheresis Device Market
28. North America Leukapheresis Device Market
29. USA Leukapheresis Device Market
30. Canada Leukapheresis Device Market
31. South America Leukapheresis Device Market
32. Brazil Leukapheresis Device Market
33. Middle East Leukapheresis Device Market
34. Africa Leukapheresis Device Market
36. Leukapheresis Device Market Competitive Landscape and Company Profiles
37. Leukapheresis Device Market Other Major and Innovative Companies
40. Leukapheresis Device Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Leukapheresis Device Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses leukapheresis device market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for leukapheresis device? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The leukapheresis device market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Device Type: Therapeutic Leukapheresis; Cytapheresis; Stem Cell Collection; Research Applications; Leukapheresis Columns and Cell Separators; Leukapheresis Disposables; Apheresis Devices2) By Component: Leukapheresis Machine; Blood Collection Set ; Medical Consumables ; Filters
3) By End User: Hospitals; Academic Research Institutes; Pharmaceutical And Biotechnology Companies; Blood Component Providers; Blood Centers
Subsegments:
1) By Therapeutic Leukapheresis: Leukemia Treatment Systems; Sepsis Treatment Leukapheresis Units; Autoimmune Disease Management Devices2) By Cytapheresis: Plateletpheresis Devices; Lymphapheresis Units; Erythrocytapheresis Systems
3) By Stem Cell Collection: Peripheral Blood Stem Cell (PBSC) Collection Devices; Umbilical Cord Blood Collection Systems; Bone Marrow Stem Cell Apheresis Systems
4) By Research Applications: Cell Separation Systems for Research and Development; Clinical Trial Apheresis Platforms; Academic Laboratory Leukapheresis Devices
5) By Leukapheresis Columns And Cell Separators: Adsorption Columns; Membrane-Based Cell Separation Systems; Centrifugal Cell Separators
6) By Leukapheresis Disposables: Tubing Sets; Needles And Catheters; Collection Bags
7) By Apheresis Devices: Continuous Flow Apheresis Machines; Portable Or Mobile Apheresis Units; Intermittent Flow Apheresis Systems
Companies Mentioned: Fresenius SE and Co. KGaA; Asahi Kasei Medical Co. Ltd; Baxter International Inc.; Grifols S.A.; TERUMO BCT INC.; Kaneka Corporation; Nikkiso Co. Ltd; Haemonetics Corporation; Miltenyi Biotec GmbH; Macopharma; B. Braun Melsungen AG; Kawasumi Laboratories Inc.; Beijing Zksk Technology Co. Ltd; Puriblood Medical Co. Ltd; Fresenius Kabi AG; JMS Co. Ltd; HemaCare Corporation; Medica Group PLC; LivaNova PLC; Cytiva; BioSafe Group SA; Terumo Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Leukapheresis Device market report include:- Fresenius SE and Co. KGaA
- Asahi Kasei Medical Co. Ltd
- Baxter International Inc.
- Grifols S.A.
- TERUMO BCT INC.
- Kaneka Corporation
- Nikkiso Co. Ltd
- Haemonetics Corporation
- Miltenyi Biotec GmbH
- Macopharma
- B. Braun Melsungen AG
- Kawasumi Laboratories Inc.
- Beijing Zksk Technology Co. Ltd
- Puriblood Medical Co. Ltd
- Fresenius Kabi AG
- JMS Co. Ltd
- HemaCare Corporation
- Medica Group PLC
- LivaNova PLC
- Cytiva
- BioSafe Group SA
- Terumo Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.76 Billion |
| Forecasted Market Value ( USD | $ 1.01 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
